Mavenclad’s regimen of dosing on five consecutive days in the first month and up to five consecutive days in the second month, with no need to dose again for a year, is a key differentiator for ...

If approved, Mavenclad could offer a more patient-friendly dosing regimen than existing MS oral drugs. Biogen’s Tecfidera (dimethyl fumarate) is taken twice daily and is associated with ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...